Dendritic cell vaccine combined hyperthermia treatment of advanced non-small cell lung cancer and nursing observation.docVIP

 PAGE \* MERGEFORMAT 10 Dendritic cell vaccine combined hyperthermia treatment of advanced non-small cell lung cancer and nursing observation Keywords: dendritic cell vaccine; hyperthermia; Care Abstract of the 14 cases of dendritic cell vaccine combined hyperthermia treatment of advanced non-small cell lung cancer patients in the observation and care summary. That the course of treatment in strict accordance with the treatment program execution, each operation before they explain to patients the treatment principles, goals, methods and side effects, psychological care throughout the treatment has always been, can the mentality of patients significantly improved during treatment, treatment-resistant subject is good. None of 14 patients serious side effects. Keywords: dendritic cell vaccine; hyperthermia; Care Dendritic cells (dendritic cells, DC) is a most powerful antigen-presenting function of professional antigen-presenting cells (APC), with DC-based tumor vaccine to treat malignant tumors is the most advanced technology of biological treatment of tumors [ 1], mainly used in the immunogenicity of a strong treatment of malignant tumors, such as malignant melanoma, prostate cancer, kidney and so on, in non-small cell lung cancer treatment is seldom used. Our hospital using the method of local hyperthermia to increase non-small cell lung cancer immunogenicity of tumor cells [2], while dendritic cell vaccine combined to improve the body’s anti-tumor immune reactivity, as the treatment of advanced non-small cell lung cancer. Our department in November 2004 ~ November 2006 into a joint treatment of 14 cases, now we are in the care and observation to explore on the following report. 1 Data and methods 1.1 General Information in November 2004 ~ November 2006, using combined therapy in patients with a total of 14 patients were recruited, aged 37 to 72 years, 10 males and 4 females, of which 6 cases of lung adenocarcinoma, lu